Your session is about to expire
← Back to Search
Vorinostat for Salivary Gland Carcinoma
Study Summary
This trial will study the side effects of pembrolizumab and vorinostat in treating patients with squamous cell head and neck cancer or salivary gland cancer.
- Salivary Gland Carcinoma
- Squamous Cell Carcinoma
- Salivary Gland Cancer
- Nasopharyngeal Cancer
- Head and Neck Squamous Cell Carcinoma
- Nasopharyngeal Carcinoma
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2011 Phase 3 trial • 661 Patients • NCT00128102Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have received a monoclonal antibody treatment within the last 4 weeks or have not yet recovered from side effects of a treatment taken more than 4 weeks earlier.You have mental health or drug abuse problems that may affect your ability to participate in the trial.You have been free of any other type of cancer for less than 5 years.You have already received treatment for your condition before.You may be eligible to receive another dose of MK-3475 if specific conditions are met.You have participated in a study involving an experimental drug or device within the past 4 weeks.You have a condition that weakens your immune system or have taken medications that lower your immune system within the past week.You have an autoimmune disease that requires regular medication or has been severe in the past 3 months.
- Group 1: Treatment (vorinostat, pembrolizumab)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What has Vorinostat traditionally been employed to treat?
"For the treatment of malignant neoplasms, Vorinostat is frequently employed. Additionally, this medication can be beneficial for those suffering from unresectable melanoma and progressive cutaneous t-cell lymphoma with a microsatellite instability high mutation."
Are any new participants able to join this trial currently?
"This clinical trial is no longer accepting participants, with the initial posting taking place on October 8th 2015 and the last update having been made on August 23rd 2022. If you are looking for other trials to participate in, there are currently 3784 studies involving squamous cell carcinoma that are actively recruiting as well as 986 related to Vorinostat."
What is the number of individuals engaging in this medical research?
"This clinical trial has ceased recruitment activities. Initially posted on October 8th, 2015 and last updated August 23rd 2022, this research is no longer accepting applicants. Those in search of other studies may find 3784 squamous cell carcinoma trials and 986 Vorinostat programs actively recruiting participants."
Are there any other reports on Vorinostat that can be referenced?
"At the present moment, 986 clinical trials are in-progress for Vorinostat. 124 of these studies are at Phase 3 and there is a plethora of locations across America hosting research on this medication, with Sacramento being the primary city."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger